Cara Wright

Dr. Cara Wright

Animal Health, Merck and Co., Rahway, New Jersey, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
CPChrissie Pariseau
Chrissie Pariseau
KJKaitlyn James
Kaitlyn James
BCBryant M Craig
Bryant M Craig
DCDuane Chappell
Duane Chappell
WVWendy Vaala
Wendy Vaala
NPNicola Pusterla
Nicola Pusterla
Equine rhinitis B virus is a lesser-known equine respiratory pathogen that is being detected with increasing frequency via a voluntary upper respiratory biosurveillance program in the United States. This program received 8684 nasal swab submissions during the years 2012–2023. The nasal swabs were submitted for qPCR testing for six common upper respiratory pathogens: Streptococcus equi subspecies equi (S. equi), equine influenza virus (EIV), equine herpesvirus type 1 (EHV-1), equine herpesvirus type 4 (EHV-4), equine rhinitis A virus (ERAV), and equine rhinitis B virus (ERBV). The overall ERBV qPCR-positivity rate was 5.08% (441/8684). ERBV was detected as a single pathogen in 291 cases (65.99% of positives, 291/441) and was detected as a coinfection with at least one other respiratory pathogen in 150 cases (34.01%, 150/441). Young horses, less than a year of age, with acute onset of fever and respiratory signs and horses used for competition are more likely to test qPCR-positive for ERBV. Horses with ERBV may present with fever, nasal discharge, ocular discharge, and/or cough. Coinfection is a common feature of ERBV infection and S. equi, EHV-4 and EIV were the most common pathogens coinfected with ERBV. This report provides important information regarding the clinical relevance of ERBV in the horse and begins investigating the impact of coinfection on clinical disease.

25 April 2025 in Viruses
Verified
Journal Article
Open access
PDF file
KJKaitlyn James
Kaitlyn James
DCDuane Chappell
Duane Chappell
BCBryant M Craig
Bryant M Craig
CPChrissie Pariseau
Chrissie Pariseau
CWCara Wright
Cara Wright
NPNicola Pusterla
Nicola Pusterla
The purpose of this study was to determine any associations of EHV-2, EHV-5, and dual infection with EHV-2/-5 with demographic parameters, clinical signs, and coinfection with other common respiratory pathogens. Nasal swabs collected from 9737 horses were tested for EHV-2 and EHV-5, as well as EHV-1, EHV-4, EIV, S equi, ERAV, and ERBV, by qPCR. Clinical signs and demographic parameters were recorded, and prevalence factors were evaluated for significance regarding EHV-2 and/or EHV-5 infection. Out of the 9737 horses in this study, 17.8% tested EHV-2-positive (n = 1731), 15.8% tested EHV-5-positive (n = 1536), 33.4% tested positive for both viruses EHV-2/-5 (n = 3247), and 33.1% tested negative for both viruses (n = 3223). When comparing EHV-2 and/or EHV-5 infected horses to horses testing qPCR-negative for both viruses, horses infected with EHV-2 alone were more likely to be younger Thoroughbreds with a history of recent transportation, presenting with fever, and having a higher rate of coinfections with EHV-4 and S. equi. Horses infected with EHV-5 alone were less likely to be used for pleasure purposes, had fewer clinical signs, and were more likely to be coinfected with EHV-4. Horses dually infected with EHV-2 and EHV-5 were much more likely to be younger, used for competition, presenting with a fever, and coinfected with additional respiratory pathogens. It is apparent from the study population that horses infected with EHV-2 alone or in combination with EHV-5 had breed predilections, greater frequency of clinical signs, and a higher rate of coinfections with EHV-4, ERBV, and S. equi.